Sunday 18 October 2026
Export BRVE’s income statement to Excel — free account
Braveheart Bio, Inc.
BRVE
Insiders bought in the last twelve months.
18.71
0.84
−4.30%
Follow BRVE
| Dec '25 | |
|---|---|
Current Ratio |
17.03 |
Net Debt/EBITDA |
1.34 |
Debt/Assets |
0.00% |
Debt/Equity |
0.00 |
Operating CF/Net income |
0.03 |
| 0.00% | |
| 0.00% | |
ROIC |
0.00% |
Return on Tangible Assets |
(78.60%) |
Research and Development Expense of Revenue |
0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% |
Intangible Assets out of Total Assets |
0.00 |
Share Based Compensation of Revenue |
0.00% |
Free Cash Flow per Share |
(0.52) |
Cash per Share |
23.22 |
Shareholders Equity per Share |
(17.15) |
Interest Debt per Share |
0.00 |
Book value per Share |
(17.15) |
Free Cash Flow |
(2.01) |
Working Capital |
84.04 |
Net Current Asset Value |
(65.94) |
| Other line items | |
Quick Ratio |
17.01 |
Cash ROIC |
(8.65%) |
Average Days of Payables |
0.00 |
Revenue per Share |
0.00 |
Operating CF per Share |
(0.52) |
Capex per Share |
0.00 |
Columns are period end dates · fundamentals updated 1 Oct 2026